Board of Directors

Jean-Pierre Bizzari

Jean-Pierre Bizzari is a highly experienced oncologist who has been successfully bringing innovative cancer treatments to market for over 35 years, overseeing clinical development in companies including Rhône-Poulenc, Sanofi-Aventis, Celgene, Servier and Halozyme. Dr Bizzari is a member of the Scientific Advisory Board of the French National Cancer Institute and the Board of the European Organization for Research and Treatment of Cancer, as well as serving as the Chairman of its New Drug Committee. He is on the Boards of Halozyme, ADC Therapeutics and Aprea Therapeutics and an Observer on the Board of Directors at Smart Immune.

Grégoire Cayatte

Independent member, Partner at TechLife

Grégoire Cayatte is Managing Partner and Co-Founder of TechLife Capital, an independent growth equity fund that specializes in healthcare and tech industries. After spending 5 years in equity transactions at Lazard and Paribas, he became Director of Strategy, Development and Finance at Devoteam, a listed technology services company, where he led more than 50 acquisitions in 20 countries and played a key role in the creation of 7 platforms, notably in cybersecurity, cloud migration and digital transformation. In the healthcare sector, Grégoire is a member of the supervisory boards of Evolutis, Flash Therapeutics, Mitem Pharma, MyData-Trust, Quinten and XPath. He is a graduate of École Polytechnique, École des Ponts ParisTech and SciencesPo Paris.

Dominique Costantini

Independent member, President and CEO of Ose Therapeutics

Dominique is an immunologist MD with more than 20 years of experience in the pharmaceutical industry. She has accompanied many therapeutic innovations internationally in the field of oncology. She founded BioAlliance Pharma and led the IPO of the company on Euronext. Currently, she is the president and CEO of OSE Therapeutics.

Federico Mingozzi

Independent member, CEO

Federico Mingozzi currently serves as the CEO of a US-based biotech company and is a Non-Executive Director of Sensorion’s Board of Directors. Previously, he held the positions of Chief Science Officer and Chief Technology Officer at Spark Therapeutics. Federico's expertise in gene therapy vectors and immune system interactions is widely recognized and he has made significant contributions to the field. His previous positions include the Head of the Immunology and Liver Gene Transfer Unit at Genethon, Research Director at the French National Institute of Health and Medical Research (INSERM) in France, and Director at the Children’s Hospital of Philadelphia.

Pablo Silveri

Independent member, CFO and co-founder of Nuqlea

Pablo Silveri is the Chief Finance Officer and Co-founder of Nuqlea, a B2B digital marketplace for construction and habitat, and Smart Immune’s former Chief Financial Officer. Pablo is a corporate finance expert who held managing roles at the Dow Chemical Company, where he worked for 25 years. Before joining Smart Immune in 2019, Pablo was the Latin America Finance Director at Dow. He is also a Board member of the Spanish company, Auravant.